-
International Journal of Chronic Obstructive Pulmonary Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population
Original Research
(2605) Views (929) Full article downloads
Authors: Amir Sharafkhaneh, Nancy J Petersen, Hong-Jen Yu, et al
Published Date April 2010
Volume 2010:5 Pages 125 - 132
DOI: http://dx.doi.org/10.2147/COPD.S8047
Amir Sharafkhaneh1,2, Nancy J Petersen2, Hong-Jen Yu2, Anand A Dalal3, Michael L Johnson2,4, Nicola A Hanania1
1Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA; 2Houston VA HSR&D Center of Excellence, Department of Veterans Affairs Medical Center, Houston, TX, USA; 3GlaxoSmithKline, Research Triangle Park, NC, USA; 4University of Houston, College of Pharmacy, Houston, TX,USA
Background: Health care utilization and costs among US veterans with chronic obstructive pulmonary disease (COPD) were compared with those in veterans without COPD.
Methods: A cohort of veterans with COPD was matched for age, sex, race, and index fiscal year to a cohort of veterans without COPD (controls) using data from the Veterans Integrated Service Network (VISN) 16 from 10/1/1997 to 9/30/2004. Annual total and respiratory-related health care service utilization, costs of care, comorbidities, and respiratory medication use at the time of diagnosis were assessed.
Results: A total of 59,906 patients with COPD were identified for a 7-year period prevalence of 8.2%, or 82 per 1000 population. Patients with COPD compared with controls had significantly higher all-cause and respiratory-related inpatient and outpatient health care utilization for every parameter examined including mean numbers of physician encounters, other outpatient encounters, emergency room visits, acute inpatient discharges, total bed days of care, and percentage of patients with any emergency room visits or any acute inpatient discharge. Patients with COPD had statistically significantly higher mean outpatient, inpatient, pharmacy, and total costs than the control group. The mean Charlson comorbidity index in patients with COPD was 1 point higher than in controls (2.85 versus 1.84, P < 0.001). 60% of COPD patients were prescribed medications recommended in treatment guidelines at diagnosis.
Conclusion: Veterans with COPD compared with those without COPD suffer a tremendous disease burden manifested by higher rates of all-cause and respiratory-related health care utilization and costs and a high prevalence of comorbidities. Furthermore, COPD patients do not receive appropriate treatment for their disease on diagnosis.
Keywords: chronic obstructive pulmonary disease (COPD), veterans, health care utilization, costs, respiratory medicine, VA, economic burden, burden of illness
Other articles by Dr Anand Dalal
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease
Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009
Direct costs of chronic obstructive pulmonary disease among managed care patients
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
Validation of alternate modes of administration of the lung function questionnaire (LFQ) in subjects with smoking history
Readers of this article also read:
Clinical relevance of maximal inspiratory pressure: determination in COPD exacerbation
Modified BODE indexes: Agreement between multidimensional prognostic systems based on oxygen uptake
Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies
Changes in six-minute walking distance during pulmonary rehabilitation in patients with COPD and in healthy subjects
Tiotropium bromide inhibits TGF-ß-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro
Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
Direct costs of chronic obstructive pulmonary disease among managed care patients
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims
Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
- Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
- The pathophysiology of bronchiectasis
- Exacerbation rate, health status and mortality in COPD – a review of potential interventions




